Follicular Lymphoma Grade 3b
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma Grade 3b.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment [NA]
Clinical trial comparing geriatric-guided care versus conventional care in elderly unfit/frail patients with Diffuse Large B-Cell Lymphoma a…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]
Phase 1 trial evaluating autologous CD22 CAR T cells in adults with recurrent or refractory B-cell malignancies has completed enrollment. Re…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of NKTR-255 in combination with CAR-T cell therapy for relapsed or refractory large B-c…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T [Phase 2]
Phase 2 clinical trial evaluating Odronextamab for relapsed or refractory large B-cell lymphomas before CAR-T therapy; the study is currentl…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]
Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS other · 2026-01-08Clinical Trial Update: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial update on mosunetuzumab in combination with platinum-based salvage chemotherapy for relapsed/refractory aggressive B-…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment [Phase 2]
This SWOG Cancer Research Network Phase 2 trial is evaluating adding drugs to standard therapy for large B-cell lymphoma that has returned o…
-
CLINICAL_TRIALS other · 2025-10-06Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large …
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial assessing the combination of loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B-cell lymphoma…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of PL001, a CD19 CAR-T cell therapy, for relapsed or refractory B-cell lymphoma. The …
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
This clinical trial registry entry describes a long-term follow-up study of a lentiviral-based gene-edited immune cell therapy for several B…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]
A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial comparing denintuzumab mafodotin plus RICE versus RICE alone in diffuse large B-cell lymphoma; the study is terminated with re…
-
CLINICAL_TRIALS research · 2017-11-14Clinical Trial Update: R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B [Phase 3]
Phase 3 randomized trial comparing R-CEOP-90/70 versus R-CHOP-50 for Diffuse large B-cell lymphoma and Follicular lymphoma grade 3B; current…
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 [Phase 3]
This update reports the completion of a multicentre, randomized Phase III trial evaluating rituximab as maintenance therapy versus observati…